Joongho John Joh

Dr. Joongho John Joh

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
SKSujita Khanal
Sujita Khanal
BSBrian S. Shumway
Brian S. Shumway
MZMaryam Zahin
Maryam Zahin
RRRebecca A. Redman
Rebecca A. Redman
JSJohn D. Strickley
John D. Strickley
JJJoongho John Joh
Joongho John Joh
Viral DNA integration and methylation of human papillomavirus type 16 in high-grade oral epithelial dysplasia and head and neck squamous cell carcinoma Viral DNA integration and methylation of human papillomavirus type 16 in high-grade oral epithelial dysplasia and head and neck squamous cell carcinoma

1 October 2017 in Experimental and Molecular Pathology
Verified
Journal Article
Open access
JJJoongho John Joh
Joongho John Joh
PCPaula M. Chilton
Paula M. Chilton
SWSarah A. Wilcher
Sarah A. Wilcher
MZMaryam Zahin
Maryam Zahin
JPJino Park
Jino Park
AJAlfred B. Jenson
Alfred B. Jenson
Previous studies of naturally occurring mouse papillomavirus (PV) MmuPV1-induced tumors in B6.Cg-Foxn1nu/nu mice suggest that T cell deficiency is necessary and sufficient for the development of such tumors. To confirm this, MmuPV1-induced tumors were transplanted from T cell-deficient mice into immunocompetent congenic mice. Consequently, the tumors regressed and eventually disappeared. The elimination of MmuPV1-infected skin/tumors in immunocompetent mice was consistent with the induction of antitumor T cell immunity. This was confirmed by adoptive cell experiments using hyperimmune splenocytes collected from graft-recipient mice. In the present study, such splenocytes were injected into T cell-deficient mice infected with MmuPV1, and they eliminated both early-stage and fully formed tumors. We clearly show that anti-tumor T cell immunity activated during tumor regression in immunocompetent mice effectively eliminates tumors developing in T cell-deficient congenic mice. The results corroborate the notion that PV-induced tumors are strongly linked to the immune status of the host, and that PV antigens are major anti-tumor antigens. Successful anti-PV T cell responses should, therefore, lead to effective anti-tumor immune therapy in human PV-infected patients.

1 October 2015 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
SKSujita Khanal
Sujita Khanal
JJJoongho John Joh
Joongho John Joh
AKAmy M. Kwon
Amy M. Kwon
MZMaryam Zahin
Maryam Zahin
CPCesar Augusto Perez
Cesar Augusto Perez
RRRebecca Ann Redman
Rebecca Ann Redman

29 September 2022 in JID Innovations
Verified
Journal Article
Open access
LJLuke H. Johnson
Luke H. Johnson
HSHeehwa G. Son
Heehwa G. Son
DHDat Thinh Ha
Dat Thinh Ha
JSJohn D. Strickley
John D. Strickley
JJJoongho John Joh
Joongho John Joh
SDShadmehr Demehri
Shadmehr Demehri
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer, with increased incidence in immunosuppressed patients. β-Human papillomavirus has been proposed as a contributor to cSCC risk partly on the basis of increased β-human papillomavirus viral load and seropositivity observed among patients with cSCC. Experimental data in mice colonized with mouse papillomavirus type 1 suggest that T cell immunity against β-human papillomavirus suppresses skin cancer in immunocompetent hosts, and the loss of this immunity leads to the increased risk of cSCC. In this study, we show that CD8+ T cell depletion in mouse papillomavirus type 1‒colonized mice that underwent skin carcinogenesis protocol led to increased viral load in the skin and seropositivity for anti‒mouse papillomavirus type 1 antibodies. These findings provide evidence that compromised T cell immunity can be the link that connects increased β-human papillomavirus detection to cSCC risk.

26 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
LJLuke Johnson
Luke Johnson
DHDat T. Ha
Dat T. Ha
MHMelissa B. Hall
Melissa B. Hall
GSGregory Shoemaker
Gregory Shoemaker
PBPaul A. Bevins
Paul A. Bevins
JJJoongho John Joh
Joongho John Joh
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( ) with 100% specificity as a predictive test.

1 December 2020 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
SKSujita Khanal
Sujita Khanal
JSJohn D. Strickley
John D. Strickley
THThinh Ha
Thinh Ha
SDShadmehr Demehri
Shadmehr Demehri
SGShin-Je Ghim
Shin-Je Ghim
JJJoongho John Joh
Joongho John Joh